|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAGEA3 |
Gene summary for MAGEA3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAGEA3 | Gene ID | 4102 |
| Gene name | MAGE family member A3 | |
| Gene Alias | CT1.3 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P43357 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4102 | MAGEA3 | LZE2T | Human | Esophagus | ESCC | 7.52e-18 | 1.19e+00 | 0.082 |
| 4102 | MAGEA3 | LZE4T | Human | Esophagus | ESCC | 2.06e-46 | 1.15e+00 | 0.0811 |
| 4102 | MAGEA3 | LZE5T | Human | Esophagus | ESCC | 1.57e-03 | 3.08e-01 | 0.0514 |
| 4102 | MAGEA3 | LZE8T | Human | Esophagus | ESCC | 6.02e-35 | 1.06e+00 | 0.067 |
| 4102 | MAGEA3 | LZE22D1 | Human | Esophagus | HGIN | 4.30e-07 | 4.26e-01 | 0.0595 |
| 4102 | MAGEA3 | LZE22T | Human | Esophagus | ESCC | 1.02e-18 | 1.36e+00 | 0.068 |
| 4102 | MAGEA3 | LZE24T | Human | Esophagus | ESCC | 5.14e-70 | 1.79e+00 | 0.0596 |
| 4102 | MAGEA3 | LZE22D3 | Human | Esophagus | HGIN | 4.92e-04 | 7.78e-01 | 0.0653 |
| 4102 | MAGEA3 | P1T-E | Human | Esophagus | ESCC | 1.83e-27 | 1.95e+00 | 0.0875 |
| 4102 | MAGEA3 | P2T-E | Human | Esophagus | ESCC | 6.31e-48 | 8.37e-01 | 0.1177 |
| 4102 | MAGEA3 | P4T-E | Human | Esophagus | ESCC | 1.23e-56 | 1.14e+00 | 0.1323 |
| 4102 | MAGEA3 | P5T-E | Human | Esophagus | ESCC | 5.53e-63 | 1.28e+00 | 0.1327 |
| 4102 | MAGEA3 | P9T-E | Human | Esophagus | ESCC | 5.27e-53 | 1.16e+00 | 0.1131 |
| 4102 | MAGEA3 | P11T-E | Human | Esophagus | ESCC | 6.73e-20 | 8.07e-01 | 0.1426 |
| 4102 | MAGEA3 | P15T-E | Human | Esophagus | ESCC | 2.56e-55 | 1.12e+00 | 0.1149 |
| 4102 | MAGEA3 | P17T-E | Human | Esophagus | ESCC | 1.36e-23 | 1.21e+00 | 0.1278 |
| 4102 | MAGEA3 | P19T-E | Human | Esophagus | ESCC | 1.65e-10 | 1.49e+00 | 0.1662 |
| 4102 | MAGEA3 | P20T-E | Human | Esophagus | ESCC | 3.59e-80 | 1.69e+00 | 0.1124 |
| 4102 | MAGEA3 | P21T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.76e-01 | 0.1617 |
| 4102 | MAGEA3 | P23T-E | Human | Esophagus | ESCC | 1.60e-80 | 2.32e+00 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009719327 | Esophagus | HGIN | intrinsic apoptotic signaling pathway | 90/2587 | 288/18723 | 1.50e-14 | 2.80e-12 | 90 |
| GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
| GO:200124227 | Esophagus | HGIN | regulation of intrinsic apoptotic signaling pathway | 58/2587 | 164/18723 | 2.57e-12 | 3.58e-10 | 58 |
| GO:200123327 | Esophagus | HGIN | regulation of apoptotic signaling pathway | 97/2587 | 356/18723 | 1.36e-11 | 1.57e-09 | 97 |
| GO:000989520 | Esophagus | HGIN | negative regulation of catabolic process | 87/2587 | 320/18723 | 1.74e-10 | 1.68e-08 | 87 |
| GO:003133026 | Esophagus | HGIN | negative regulation of cellular catabolic process | 74/2587 | 262/18723 | 6.27e-10 | 5.30e-08 | 74 |
| GO:001050616 | Esophagus | HGIN | regulation of autophagy | 84/2587 | 317/18723 | 1.39e-09 | 1.08e-07 | 84 |
| GO:004328126 | Esophagus | HGIN | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 59/2587 | 209/18723 | 3.39e-08 | 1.97e-06 | 59 |
| GO:190589725 | Esophagus | HGIN | regulation of response to endoplasmic reticulum stress | 31/2587 | 82/18723 | 5.25e-08 | 2.91e-06 | 31 |
| GO:200011626 | Esophagus | HGIN | regulation of cysteine-type endopeptidase activity | 63/2587 | 235/18723 | 9.71e-08 | 5.02e-06 | 63 |
| GO:007005920 | Esophagus | HGIN | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 25/2587 | 63/18723 | 3.41e-07 | 1.57e-05 | 25 |
| GO:200123427 | Esophagus | HGIN | negative regulation of apoptotic signaling pathway | 59/2587 | 224/18723 | 4.68e-07 | 2.07e-05 | 59 |
| GO:200124325 | Esophagus | HGIN | negative regulation of intrinsic apoptotic signaling pathway | 33/2587 | 98/18723 | 4.73e-07 | 2.07e-05 | 33 |
| GO:005254726 | Esophagus | HGIN | regulation of peptidase activity | 102/2587 | 461/18723 | 6.29e-07 | 2.72e-05 | 102 |
| GO:005254826 | Esophagus | HGIN | regulation of endopeptidase activity | 96/2587 | 432/18723 | 1.09e-06 | 4.30e-05 | 96 |
| GO:19022359 | Esophagus | HGIN | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 15/2587 | 32/18723 | 6.76e-06 | 2.08e-04 | 15 |
| GO:190357320 | Esophagus | HGIN | negative regulation of response to endoplasmic reticulum stress | 18/2587 | 44/18723 | 8.97e-06 | 2.64e-04 | 18 |
| GO:005160417 | Esophagus | HGIN | protein maturation | 68/2587 | 294/18723 | 9.77e-06 | 2.86e-04 | 68 |
| GO:00105076 | Esophagus | HGIN | negative regulation of autophagy | 27/2587 | 85/18723 | 1.72e-05 | 4.71e-04 | 27 |
| GO:190223620 | Esophagus | HGIN | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 11/2587 | 20/18723 | 1.73e-05 | 4.71e-04 | 11 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAGEA3 | SNV | Missense_Mutation | c.418N>A | p.Val140Ile | p.V140I | P43357 | protein_coding | tolerated(1) | benign(0) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAGEA3 | SNV | Missense_Mutation | novel | c.711N>G | p.Ser237Arg | p.S237R | P43357 | protein_coding | deleterious(0.02) | possibly_damaging(0.582) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAGEA3 | SNV | Missense_Mutation | c.940N>A | p.Glu314Lys | p.E314K | P43357 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAGEA3 | insertion | Frame_Shift_Ins | novel | c.763_764insCTCCTACGATGGCCTGCTGGGTG | p.Tyr255SerfsTer38 | p.Y255Sfs*38 | P43357 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | ||
| MAGEA3 | SNV | Missense_Mutation | c.326N>A | p.Leu109His | p.L109H | P43357 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| MAGEA3 | SNV | Missense_Mutation | c.892C>T | p.His298Tyr | p.H298Y | P43357 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAGEA3 | SNV | Missense_Mutation | novel | c.295N>A | p.Pro99Thr | p.P99T | P43357 | protein_coding | tolerated(0.1) | benign(0.231) | TCGA-VS-A8EC-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| MAGEA3 | SNV | Missense_Mutation | novel | c.296N>T | p.Pro99Leu | p.P99L | P43357 | protein_coding | deleterious(0.01) | benign(0.231) | TCGA-VS-A8EC-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| MAGEA3 | SNV | Missense_Mutation | novel | c.228N>G | p.Asn76Lys | p.N76K | P43357 | protein_coding | tolerated(0.98) | benign(0.076) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAGEA3 | SNV | Missense_Mutation | novel | c.151G>T | p.Gly51Trp | p.G51W | P43357 | protein_coding | deleterious(0.02) | probably_damaging(0.955) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | Astuprotimut-R | ASTUPROTIMUT-R | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | KITE-718 | |||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | vaccine | EP-2101 | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | GL-0817 | BIROPEPIMUT-S | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | MAGE-A3 | ASTUPROTIMUT-R | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | vaccine | GSK1572932A | ASTUPROTIMUT-R | |
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | INCOMPLETE FREUND&APOS;S ADJUVANT | 10546159 | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | DNA VACCINE | 15750833 | ||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | Polynoma-1 | |||
| 4102 | MAGEA3 | ENZYME, DRUGGABLE GENOME | IDM-2101 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |